Stevens Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stevens Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-565	Closed	-$258K	–	204
2025 Q3	$258K	Buy	+565	New	+$230K	0.03%	219
2024 Q2	–	Sell	-1,390	Closed	-$208K	–	221
2024 Q1	$208K	Buy	+1,390	New	+$232K	0.04%	262
2019 Q3	–	Sell	-14,571	Closed	-$1.06M	–	546
2019 Q2	$1.06M	Buy	+14,571	New	+$1.12M	0.05%	358
2018 Q4	–	Sell	-7,041	Closed	-$616K	–	680
2018 Q3	$616K	Buy	+7,041	New	+$708K	0.02%	500
2016 Q4	–	Sell	-15,286	Closed	-$1.04M	–	852
2016 Q3	$1.04M	Buy	+15,286	New	+$1.08M	0.04%	403
2016 Q2	–	Sell	-11,168	Closed	-$701K	–	883
2016 Q1	$701K	Buy	+11,168	New	+$743K	0.03%	499
2015 Q3	–	Sell	-4,603	Closed	-$552K	–	961
2015 Q2	$552K	Buy	4,603 +467	+11%	+$55.8K	0.02%	592
2015 Q1	$432K	Sell	4,136 -8,894	-68%	-$901K	0.02%	621
2014 Q4	$1.26M	Buy	+13,030	New	+$1.21M	0.04%	372
2014 Q3	–	Sell	-49,810	Closed	-$3.15M	–	975
2014 Q2	$3.15M	Buy	49,810 +40,595	+441%	+$2.41M	0.08%	270
2014 Q1	$619K	Buy	+9,215	New	+$713K	0.02%	601

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Stevens Capital Management's ALNY Position: Q4 2025 in Review

Stevens Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 565 shares — an estimated $258K sold.

Stevens Capital Management first reported a position in ALNY in Q1 2014 and held it in 11 quarters. The position peaked at $3.15M in Q2 2014. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Stevens Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Stevens Capital Management sold 565 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $258K.
Stevens Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Stevens Capital Management's Alnylam Pharmaceuticals position peaked at $3.15M in Q2 2014.
848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Stevens Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.